# OnCo record imvigor011 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/imvigor011/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "imvigor011", "NCT04660344" ;
  schema:name "IMvigor011"@en ;
  schema:description "The first trial to use a blood test for leftover cancer to decide who gets immunotherapy, and it worked."@en ;
  schema:url <https://onco.cc/trials/imvigor011/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04660344> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2021-05-03" ;
  onco:cancers <https://onco.cc/cancers/urothelial/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/signatera/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/> ;
  onco:people <https://onco.cc/people/thomas-powles/> .